Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

5 treatments under study, led by Oblimersen Sodium

Related Conditions

Often studied with 20 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Phase 1 (1)
Phase 2 (1)

Trial Status

Completed2

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT01155258Phase 1Completed

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

NCT00079131Phase 2Completed

Oblimersen in Treating Patients With Merkel Cell Carcinoma

Showing all 2 trials

Research Network

Common Treatments

  • Oblimersen Sodium1
  • Temsirolimus1
  • Vinorelbine Ditartrate1
  • Pharmacological Study1
  • Laboratory Biomarker Analysis1

Active Sponsors

  • National Cancer Institute (NCI)1
  • University of Southern California1
  • Wyeth is now a wholly owned subsidiary of Pfizer1

Top Investigators

Related Conditions

  • Recurrent Neuroendocrine Carcinoma Of The Skin2
  • Stage Iii Neuroendocrine Carcinoma Of The Skin2
  • Recurrent Pheochromocytoma1
  • Recurrent Prostate Cancer1
  • Stage Ivb Cervical Cancer1

Activity Timeline